logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9957229 B1

PDFFull Text
Date of Patent:
May. 01, 2018

Filed:

May. 23, 2017

Amido compounds and their use as pharmaceuticals

Applicants:

Incyte Corporation, Wilmington, DE (US);

Incyte Holdings Corporation, Wilmington, DE (US);

Inventors:

Wenqing Yao, Chadds Ford, PA (US);

Jincong Zhuo, Garnet Valley, PA (US);

Meizhong Xu, Hockessin, DE (US);

Colin Zhang, Ambler, PA (US);

Brian W. Metcalf, Moraga, CA (US);

Chunhong He, Chadds Ford, PA (US);

Ding-Quan Qian, Newark, DE (US);

Assignees:

Incyte Holdings Corporation, Wilmington, DE (US);

Incyte Corporation, Wilmington, DE (US);

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Joseph R Kosack

Int. Cl.
CPC ...
C07D 471/10 (2006.01); C07D 207/06 (2006.01); A61K 31/407 (2006.01); C07D 491/107 (2006.01); C07D 513/10 (2006.01); C07D 498/20 (2006.01); C07D 495/04 (2006.01); C07D 493/10 (2006.01); C07D 491/20 (2006.01); C07D 491/10 (2006.01); C07D 487/10 (2006.01); C07D 487/08 (2006.01); C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 417/04 (2006.01); C07D 413/14 (2006.01); C07D 413/10 (2006.01); C07D 405/14 (2006.01); C07D 405/04 (2006.01); C07D 403/04 (2006.01); C07D 401/14 (2006.01); C07D 401/10 (2006.01); C07D 401/06 (2006.01); C07D 401/04 (2006.01); C07D 333/34 (2006.01); C07D 295/185 (2006.01); C07D 221/20 (2006.01); C07D 217/26 (2006.01); C07D 217/06 (2006.01); C07D 213/38 (2006.01); C07D 211/70 (2006.01); C07D 211/66 (2006.01); C07D 211/64 (2006.01); C07D 211/58 (2006.01); C07D 211/52 (2006.01); C07D 211/48 (2006.01); C07D 211/46 (2006.01); C07D 211/34 (2006.01); C07D 211/22 (2006.01); C07D 211/18 (2006.01); C07D 211/16 (2006.01); C07D 209/70 (2006.01); C07D 209/62 (2006.01); C07D 209/52 (2006.01); C07D 209/44 (2006.01); C07D 209/42 (2006.01); C07D 209/08 (2006.01); C07D 207/27 (2006.01); C07D 207/16 (2006.01); C07D 207/14 (2006.01); C07D 207/12 (2006.01); C07D 207/10 (2006.01); C07D 207/08 (2006.01); A61K 31/4439 (2006.01);
U.S. Cl.
CPC ...
C07D 207/06 (2013.01); A61K 31/407 (2013.01); A61K 31/4439 (2013.01); C07D 207/08 (2013.01); C07D 207/10 (2013.01); C07D 207/12 (2013.01); C07D 207/14 (2013.01); C07D 207/16 (2013.01); C07D 207/27 (2013.01); C07D 209/08 (2013.01); C07D 209/42 (2013.01); C07D 209/44 (2013.01); C07D 209/52 (2013.01); C07D 209/62 (2013.01); C07D 209/70 (2013.01); C07D 211/16 (2013.01); C07D 211/18 (2013.01); C07D 211/22 (2013.01); C07D 211/34 (2013.01); C07D 211/46 (2013.01); C07D 211/48 (2013.01); C07D 211/52 (2013.01); C07D 211/58 (2013.01); C07D 211/64 (2013.01); C07D 211/66 (2013.01); C07D 211/70 (2013.01); C07D 213/38 (2013.01); C07D 217/06 (2013.01); C07D 217/26 (2013.01); C07D 221/20 (2013.01); C07D 295/185 (2013.01); C07D 333/34 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01); C07D 491/10 (2013.01); C07D 491/107 (2013.01); C07D 491/20 (2013.01); C07D 493/10 (2013.01); C07D 495/04 (2013.01); C07D 498/20 (2013.01); C07D 513/10 (2013.01);
Abstract

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

Find Patent Forward Citations

Loading…